PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/12, C07K 14/805, C12N 1/21

A3

(11) International Publication Number:

WO 98/50430

(43) International Publication Date:

12 November 1998 (12.11.98)

(21) International Application Number:

PCT/US98/08861

(22) International Filing Date:

1 May 1998 (01.05.98)

(30) Priority Data:

60/045,364 60/057,986 2 May 1997 (02.05.97)

5 September 1997 (05.09.97) U

US US (74

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications

US Filed on 60/045,364 (CIP)

2 May 1997 (02.05.97) 60/057,986 (CIP)

US Filed on

5 September 1997 (05.09.97)

(71) Applicants (for all designated States except US): SOMATOGEN, INC. [US/US]; Suite FD-1, 2545 Central Avenue, Boulder, CO 80301 (US). WILLIAM MARSH RICE UNIVERSITY [US/US]; Institute of Bioscience & Bioengineering, 6100 South Main, Houston, TX 77005 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WEICKERT, Michael, J. [US/US]; 7565 Charmant Drive #311, San Diego, CA 92122 (US). GLASCOCK, Christopher, B. [US/US]; 919 Eldorado

Lane, Louisville, CO 80027 (US). MATHEWS, Antony, J. [NZ/US]; 1639 Spruce Street, Boulder, CO 80302 (US). LEMON, Douglas, D. [US/US]; 639 Fireside, Louisville, CO 80027 (US). DOHERTY, Daniel, H. [US/US]; 719 Ithaca Drive, Boulder, CO 80303 (US). OLSON, John, S. [US/US]; 4407 Lumbar, Houston, TX 77096–4418 (US).

(74) Agent: BROWN, Theresa, A.; Somatogen, Inc., Suite FD-1, 2545 Central Avenue, Boulder, CO 80301 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report: 1 April 1999 (01.04.99)

(54) Title: HEMOGLOBIN MUTANTS WITH INCREASED SOLUBLE EXPRESSION AND/OR REDUCED NITRIC OXIDE SCAVENGING

(57) Abstract

The invention relates to novel recombinant hemoglobins having reduced nitric oxide scavenging and/or increased high soluble expression. The invention further relates to methods of increasing the soluble expression of recombinant hemoglobin by adding exogenous hemin in molar excess of the heme binding sites of recombinant hemoglobin.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

	A 11	ES	Spain	LS	Lesotho	SI	Slovenia
AL	Albania Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AM		FR	France	LU	Luxembourg	SN	Senegal
AT	Austria	GA	Gabon	LV	Latvia	\mathbf{SZ}	Swaziland
AU	Australia	GB	United Kingdom	MC	Monaco	TD	Chad
AZ	Azerbaijan	GE	Georgia	MD	Republic of Moldova	TG	Togo
BA	Bosnia and Herzegovina	GH	Ghana	MG	Madagascar	тј	Tajikistan
BB	Barbados	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BE	Belgium		Greece	14114	Republic of Macedonia	TR	Turkey
BF	Burkina Faso	GR	-	ML	Mali	TT	Trinidad and Tobago
BG	Bulgaria	HU	Hungary	MN	Mongolia	UA	Ukraine
BJ	Benin	ΙE	Ireland	MR	Mauritania	UG	Uganda
BR	Brazil	IL	Israel	MW	Malawi	US	United States of America
BY	Belarus	IS	Iceland	MX	Mexico	UZ	Uzbekistan
CA	Canada	IT	Italy	NE NE	Niger	VN	Viet Nam
CF	Central African Republic	JP	Japan		Netherlands	YU	Yugoslavia
CG	Congo	KE	Kenya	NL NO		zw	Zimbabwe
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZIII	Zimotowe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		
1							

In' itional Application No PCT/US 98/08861

A. CLASSII IPC 6	FICATION OF SUBJECT MATTER C12N15/12 C07K14/805 C12N1/21			
A a a = = = !	International Potent Class Was Now (ISO)			
	o International Patent Classification (IPC) or to both national classificat SEARCHED	ion and IPC		
	ocumentation searched (classification system followed by classification	n symbols)		
IPC 6	C07K C12N	,		
Documentat	tion searched other than minimum documentation to the extent that su	ch documents are included in the fields sea	arched	
Electronic d	ata base consulted during the international search (name of data base	e and, where practical, search terms used)		
		· ,,,,		
	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages	Relevant to claim No.	
Χ	WO 97 04110 A (SOMATOGEN, INC.) 6 February 1997		5,6	
	cited in the application			
	see the whole document especially 17 and 18	examples		
		,		
	-	·/		
±				
X Furt	her documents are listed in the continuation of box C.	X Patent family members are listed i	n annex.	
° Special ca	ategories of cited documents ;	"T" later document published after the inte	rnational filing date	
"A" docume	ent defining the general state of the art which is not dered to be of particular relevance	or priority date and not in conflict with cited to understand the principle or the	the application but	
"E" earlier (document but published on or after the international	invention "X" document of particular relevance; the c	laimed invention	
"L" document which may throw doubts on priority claim(s) or involve an inventive step when the document is taken alone				
citatio	if of other apedia reason (as specified)	"Y" document of particular relevance; the c cannot be considered to involve an inv	laimed invention	
	ent referring to an oral disclosure, use, exhibition or means	document is combined with one or mo ments, such combination being obviou	re other such docu-	
	ent published prior to the international filing date but han the priority date claimed	in the art. *&" document member of the same patent	·	
Date of the	actual completion of the international search	Date of mailing of the international sea		
		0 1, 02, 99	·	
$\lfloor _ \rfloor^1$	9 January 1999	V 1, Ve. 23		
Name and	mailing address of the ISA	Authorized officer	<u> </u>	
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk			
İ	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Le Cornec, N		

Ir Tational Application No
PCT/US 98/08861

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. GLASCOCK ET AL: "Amino acid substitutions significantly affect soluble expression of recombinant hemoglobin in E.coli" ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 97, no. 0, 8 April 1997, page 298 XP002077666 WASHINGTON US & 97TH GENERAL METING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, MIAMI BEACH, FLORIDA, USA, 4 - 8 May 1997, see abstract H-85	1,3
X	HOFFMAN S J ET AL: "EXPRESSION OF FULLY FUNCTIONAL TETRAMERIC HUMAN HEMOGLOBIN IN ESCHERICHIA COLI" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 21, November 1990, pages 8521-8525, XP000647625 see abstract see page 8522, left-hand column, paragraph 2 - right-hand column, paragraph 1 see page 8521, right-hand column	5
X	L. KIGER ET AL: "Recombinant (Phe-beta63)hemoglobin shows rapid oxidation of the beta chains and low affinity, non-cooperative oxygen binding to the alpha subunits" EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 243, no. 1/2, January 1997, pages 365-373, XP002090387 see the whole document	15
А	I. PECHIK ET AL: "Crystallographic, molecular modeling and biophysical characterization of the Valine beta67 (E++): Threonine variant of hemoglobin" BIOCHEMISTRY., vol. 35, 1996, pages 1935-1945, XP002090388 EASTON, PA US see the whole document	7-20
A	WO 97 15591 A (RICE UNIVERSITY) 1 May 1997 cited in the application see page 24; example 1; table 8	1-20

l' national Application No
PCT/US 98/08861

		PC1/03 90/00001		
C.(Continua Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	A. DUMOULIN ET AL: "Two mutations in recombinant Hb bewta F41(C7)Y, K82 (EF6)D show additive effects in decreasing oxygen affinity" PROTEIN SCIENCE, vol. 5, no. 1, January 1996, pages 114-120, XP002077667	1,3,4		
Α	US 5 028 588 A (SOMATOGENETICS INTERNATIONAL, INC.) 2 July 1991 cited in the application see the whole document especially page 24 table 2, page 9 line 28-41	1-7,10, 15		
Α	TONG-JIAN SHEN ET AL: "Production of unmodified human adult hemoglobin in Escherichia coli" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 90, September 1993, pages 8108-8112, XP002077005 WASHINGTON US see abstract see page 8109	1-6		
A .	R.F. EICH ET AL: "Mechanism of NO-induced oxidation of Myoglobin and hemoglobin" BIOCHEMISTRY., vol. 35, 1996, pages 6976-6983, XP002090389 EASTON, PA US cited in the application see the whole document especially the abstract, page 6980 right column third paragraph, figure 4	7,10,15		
A	LOOKER D ET AL: "A HUMAN RECOMBINANT HAEMOGLOBIN DESIGNED FOR USE AS A BLOOD SUBSTITUTE" NATURE, vol. 356, no. 6366, 19 March 1992, pages 258-260, XP000606891			
P,X	WO 97 23631 A (SOMATOGEN, INC.) 3 July 1997 see page 52, line 17 - line 21; example 13 see page 29, line 20 - line 32	1-6		

l' national Application No PCT/US 98/08861

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	12.		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
P,X	M.J. WEICKERT ET AL: "turnover of recombinant human hemoglobin in Escherichia coli occurs rapidly for insoluble and slowly for soluble" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 348, no. 2, 15 December 1997, pages 337-346, XP002077668 see the whole document	5,6		
Γ	D.H. DOHERTY ET AL: "Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin" NATURE BIOTECHNOLOGY., vol. 16, July 1998, pages 672-676, XP002090396 UBLISHING US			

PCT/US 98/08861

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1. X	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-6

method of obtaining high expression of soluble recombinant hemoglobin.

2. Claims: 7-20

A hemoglobin mutant with reduced rate of reaction with nitric oxide.

Information on patent family members

1 national Application No PCT/US 98/08861

	locument arch report		Publication date		atent family nember(s)	Publication date
WO 970	4110	Α	06-02-1997	AU	6489996 A	18-02-1997
WO 971	5591	Α	01-05-1997	AU	7467196 A	15-05-1997
				CA	2231245 A	01-05-1997
~			****	EP	0859789 A	26-08-1998
US 502	8588	Α	02-07-1991	AT	110276 T	15-09-1994
				AU	614525 B	05-09-1991
			,	AU	1796788 A	21-12-1988
				DE	3851225 D	29-09-1994
				DE	3851225 T	06-04-1995
				EP	0358708 A	21-03-1990
				EP	0561245 A	22-09-1993
				GB	2234749 A,B	13-02-1991
				HK	50993 A	04-06-1993
			•	HU	9500388 A	28-09-1995
				WO	8809179 A	01-12-1988
				US	5449759 A	12-09-1995
				US	5563254 A	08-10-1996
				US	5661124 A	26-08-1997
				US	5776890 A	07-07-1998
WO 972	3631	Α	03-07-1997	AU	1468997 A	17-07-1997
				ΕP	0868521 A	07-10-1998